Segment Reporting

12 Months Ended

Dec. 31, 2017

Segment Reporting [Abstract]

Segment Reporting

12. Segment reporting:

The Company operates in a single industry engaging in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. Accordingly, the Company’s business is classified as a single reportable segment.

The following table presents net sales by product for each of the years ended December 31 (in thousands):

	Year ended December 31,
	2017		2016		2015
BELBUCA®	$	26,980	$	—	$	—
BUNAVAIL®		7,942		8,266		4,157
Net product sales	$	34,922	$	8,266	$	4,157